XML 18 R6.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Operating Activities    
Net loss $ (25,350) $ (26,999)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 995 1,166
Depreciation and amortization 1,156 1,187
Non-cash interest expense and other 310 478
Changes in operating assets and liabilities:    
Accounts receivable (2,158) (4,004)
Inventories (5,182) (1,942)
Prepaid expenses and other assets 2,270 (1,360)
Operating lease right of use asset 428  
Accounts payable, accrued compensation and other liabilities (1,246) (1,840)
Long-term operating lease liability (607)  
Sales rebates and discounts (351) 330
Net cash used in operating activities (29,735) (32,984)
Investing Activities    
Proceeds from the maturity of investments   52,843
Cash received from sale of Hyperimmune Business   65
Purchases of property and equipment (153) (567)
Purchases of investments   (16,534)
Net cash (used in) provided by investing activities (153) 35,807
Financing Activities    
Proceeds from issuance of common stock, warrants, and pre-funded warrants, net 20,297  
Proceeds from exercise of common stock options   564
Proceeds from the exercise of pre-funded warrants 21  
Payment of tax liability for vested equity awards (58) (807)
Net cash provided by (used in) financing activities 20,260 (243)
(Decrease) Increase in cash, cash equivalents, and restricted cash (9,628) 2,580
Cash, cash equivalents, and restricted cash at beginning of period 38,083 17,495
Cash, cash equivalents, and restricted cash at end of period $ 28,455 $ 20,075